A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (“NPC”) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations. On May 29, 2025, we changed our corporate name from “Coherus BioSciences, Inc.” to “Coherus Oncology, Inc.” to better align with our exclusive focus on proprietary innovative immuno-oncology medicines following the completion of the recent divestitures of our biosimilar businesses. On October 27, 2023, we announced that LOQTORZI was approved by the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 267M | 257M | 211M | 327M |
| Net Income | 168M | 168M | 29M | -238M | -292M | -287M |
| EPS | $1.43 | $1.43 | $0.25 | $-2.53 | $-3.76 | $-3.81 |
| Free Cash Flow | -332M | -332M | -248M | -175M | -243M | -39M |
| ROIC | -70.1% | -70.1% | 29.6% | -25.5% | -42.2% | -66.7% |
| Gross Margin | - | - | 96.7% | 38.2% | 66.8% | 82.4% |
| Debt/Equity | 0.02 | 0.02 | -1.73 | -1.18 | -1.65 | 3.41 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -181M | -181M | -200M | -203M | -257M | -264M |
| Operating Margin | 0.0% | - | -74.8% | -79.0% | -121.7% | -80.8% |
| ROE | 275.4% | 275.4% | - | - | - | -293.8% |
| Shares Outstanding | 117M | 117M | 114M | 94M | 78M | 75M |
Coherus Oncology, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
Coherus Oncology, Inc. trades at 6.8x trailing earnings, compared to its 15-year median P/E of 10.4x, suggesting it is currently Fair relative to its historical range. The company's 5-year average gross margin is 71.0%. At current prices, the estimated annualized return to fair value is +9.3%.
Coherus Oncology, Inc. (CHRS) has a current P/E ratio of 6.8, compared to its historical median P/E of 10.4. The stock is currently considered Fair based on its historical valuation range.
Coherus Oncology, Inc. (CHRS) has a 5-year average return on invested capital (ROIC) of -35.0%. This is below average and may indicate limited pricing power.
Coherus Oncology, Inc. (CHRS) has a market capitalization of $201M. It is classified as a small-cap stock.
Coherus Oncology, Inc. (CHRS) does not currently pay a regular dividend.
Based on historical P/E analysis, Coherus Oncology, Inc. (CHRS) appears fair. The current P/E of 6.8 is 34% below its historical median of 10.4. The estimated fair value CAGR (P/E method) is -25.0%.
Coherus Oncology, Inc. (CHRS) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Coherus Oncology, Inc. (CHRS) generated $-332 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Coherus Oncology, Inc. (CHRS) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Coherus Oncology, Inc. (CHRS) reported earnings per share (EPS) of $1.43 in its most recent fiscal year.
Coherus Oncology, Inc. (CHRS) has a return on equity (ROE) of 275.4%. This indicates the company generates strong returns for shareholders.
Coherus Oncology, Inc. (CHRS) has a 5-year average gross margin of 71.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for Coherus Oncology, Inc. (CHRS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Coherus Oncology, Inc. (CHRS) has a book value per share of $0.52, based on its most recent annual SEC filing.